We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Prognostic Biomarkers Predict Dengue Shock and Organ Failure

By LabMedica International staff writers
Posted on 07 Sep 2016
Print article
Image: The Cobas e 411 immunoassay analyzer (Photo courtesy of Roche Diagnostics).
Image: The Cobas e 411 immunoassay analyzer (Photo courtesy of Roche Diagnostics).
There are presently no biomarkers that can predict the incidence of dengue shock and/or organ failure, although the early identification of risk factors is important in determining appropriate management to reduce mortality.

Mortality rates among patients who have been hospitalized with severe dengue are 1.6% to 10.9%, and death in adults is mainly due to the development of dengue shock and organ dysfunction. The prognostic value of serum procalcitonin (PCT) and peripheral venous lactate (PVL) levels as biomarkers of dengue shock and/or organ failure have been evaluated.

Scientists at Mahidol University (Bangkok, Thailand) conducted a prospective observational study among adults hospitalized for confirmed viral dengue infection between October 2013 and July 2015. Of 160 patients with dengue, 128 (80.0%) patients had dengue without shock or organ failure, whereas 32 (20.0%) patients developed dengue with shock and/or organ failure. Laboratory tests were conducted at admission, including a complete blood count and blood chemistry assessment, and samples for the measurement of PCT and PVL were collected.

PCT was measured using an electrochemiluminescence method (Elecsys BRAHMS PCT, Roche Diagnostic, Mannheim, Germany) using a Roche Diagnostic Cobas e 411 immunoassay analyzer. The detection limit for the PCT assay was 0.02 ng/mL. PVL levels were measured by a colorimetric assay with an enzymatic reaction using a Cobas C Systems autoanalyzer (Roche/Hitachi, Indianapolis, IN, USA). All sera collected at admission and two weeks after admission were tested using four separate capture enzyme-linked immunosorbent assays (ELISA) for immunoglobulin M (IgM) and IgG against dengue virus and Japanese encephalitis virus.

The team found that patients with dengue shock and/or organ failure had significantly higher PCT levels and higher PVL levels, higher hemoglobin concentrations, increased hematocrit values above baseline, elevated while blood counts (WBC), higher absolute bands, increased atypical lymphocyte counts, higher alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. However, patients with dengue shock and/or organ failure had significantly lower platelet counts and albumin levels. Dengue shock patients with non-clearance of PCT and PVL expired during hospitalization.

The authors concluded that a PCT equal to or greater than 0.7 ng/mL and a PVL equal to or greater than 2.5 mmol/L were independently associated with dengue shock and/or organ failure. The combination of PCT and PVL levels could be used as prognostic biomarkers for the prediction of dengue shock and/or organ failure. The study was published on August 26, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Mahidol University
Roche Diagnostic
Roche/Hitachi
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.